Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by Analysts

Key Points

• Zura Bio Limited (NASDAQ:ZURA) has received a consensus rating of "Buy" from eight brokerage firms, with seven recommending a buy and one a strong buy.
• The average twelve-month price target for Zura Bio among analysts is $14.33, despite Oppenheimer adjusting their target price down from $19.00 to $17.00.
• The company's latest quarterly earnings report showed an EPS of ($0.19), falling short of the expected ($0.17) by $0.02.

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have been given a consensus rating of "Buy" by the eight research firms that are presently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $14.3333.

Separately, Oppenheimer dropped their target price on Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, May 9th.

Institutional Trading of Zura Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of ZURA. Raymond James Financial Inc. purchased a new position in shares of Zura Bio during the 4th quarter valued at $371,000. American Century Companies Inc. bought a new stake in Zura Bio during the fourth quarter valued at about $27,000. Prudential Financial Inc. purchased a new position in shares of Zura Bio in the fourth quarter valued at about $28,000. JPMorgan Chase & Co. lifted its position in shares of Zura Bio by 12,060.8% in the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock valued at $6,583,000 after acquiring an additional 2,611,532 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Zura Bio by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 955,426 shares of the company's stock worth $2,389,000 after acquiring an additional 42,801 shares during the period. Hedge funds and other institutional investors own 61.14% of the company's stock.

Zura Bio Trading Down 4.1%

ZURA traded down $0.06 during trading on Thursday, hitting $1.42. 232,648 shares of the company's stock traded hands, compared to its average volume of 873,455. The stock has a market capitalization of $97.09 million, a price-to-earnings ratio of -2.03 and a beta of -0.06. The company's 50 day simple moving average is $1.32 and its two-hundred day simple moving average is $1.32. Zura Bio has a 12-month low of $0.97 and a 12-month high of $5.07.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, equities analysts expect that Zura Bio will post -0.65 EPS for the current year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.